1
|
Abdullah N, Bradley D, Nisbet A, Kamarul Zaman Z, Deraman S, Mohd Noor N. Dosimetric characteristics of fabricated germanium doped optical fibres for a postal audit of therapy electron beams. Radiat Phys Chem Oxf Engl 1993 2022. [DOI: 10.1016/j.radphyschem.2022.110346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
2
|
GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer. Clin Transl Radiat Oncol 2022; 33:15-22. [PMID: 35243017 PMCID: PMC8885383 DOI: 10.1016/j.ctro.2021.12.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Accepted: 12/05/2021] [Indexed: 12/19/2022] Open
Abstract
CXB appears to be an efficacious technique for rectal cancer treatment and may allow rectal preservation in selected patients. These GEC ESTRO ACROP recommendations recommend dose schemes in for rectal CXB. These recommendations advise reporting of tumour depth to enable future refinement of dose prescription and target definition. The routine collection and publication of outcome data including patient reported outcomes (PROs) is recommended.
Purpose To issue consensus recommendations for contact X-Ray brachytherapy (CXB) for rectal cancer covering pre-treatment evaluation, treatment, dosimetric issues and follow-up. These recommendations cover CXB in the definitive and palliative setting. Methods Members of GEC ESTRO with expertise in rectal CXB issued consensus-based recommendations for CXB based on literature review and clinical experience. Levels of evidence according to the Oxford Centre for Evidence based medicine guidance are presented where possible. Results The GEC ESTRO ACROP consensus recommendations support the use of CXB to increase the chances of clinical complete remission and cure for patients who are elderly with high surgical risk, surgically unfit or refusing surgery. For palliative treatment, the use of CXB is recommended for symptomatic relief and disease control. The use of CXB in an organ-preservation setting in surgically fit patients is recommended within the setting of a clinical trial or registry. Conclusions The GEC ESTRO ACROP recommendations for CXB are provided. Recommendations towards standardisation of reporting and prescription are given. Practitioners are encouraged to follow these recommendations and to develop further clinical trials to examine this treatment modality and increase the evidence base for its use. The routine collection of outcomes both clinical and patient-reported is also encouraged.
Collapse
|
3
|
Fonseca GP, Johansen JG, Smith RL, Beaulieu L, Beddar S, Kertzscher G, Verhaegen F, Tanderup K. In vivo dosimetry in brachytherapy: Requirements and future directions for research, development, and clinical practice. PHYSICS & IMAGING IN RADIATION ONCOLOGY 2020; 16:1-11. [PMID: 33458336 PMCID: PMC7807583 DOI: 10.1016/j.phro.2020.09.002] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 08/24/2020] [Accepted: 09/17/2020] [Indexed: 12/19/2022]
Abstract
Brachytherapy can deliver high doses to the target while sparing healthy tissues due to its steep dose gradient leading to excellent clinical outcome. Treatment accuracy depends on several manual steps making brachytherapy susceptible to operational mistakes. Currently, treatment delivery verification is not routinely available and has led, in some cases, to systematic errors going unnoticed for years. The brachytherapy community promoted developments in in vivo dosimetry (IVD) through research groups and small companies. Although very few of the systems have been used clinically, it was demonstrated that the likelihood of detecting deviations from the treatment plan increases significantly with time-resolved methods. Time–resolved methods could interrupt a treatment avoiding gross errors which is not possible with time-integrated dosimetry. In addition, lower experimental uncertainties can be achieved by using source-tracking instead of direct dose measurements. However, the detector position in relation to the patient anatomy remains a main source of uncertainty. The next steps towards clinical implementation will require clinical trials and systematic reporting of errors and near-misses. It is of utmost importance for each IVD system that its sensitivity to different types of errors is well understood, so that end-users can select the most suitable method for their needs. This report aims to formulate requirements for the stakeholders (clinics, vendors, and researchers) to facilitate increased clinical use of IVD in brachytherapy. The report focuses on high dose-rate IVD in brachytherapy providing an overview and outlining the need for further development and research.
Collapse
Affiliation(s)
- Gabriel P Fonseca
- Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, Doctor Tanslaan 12, 6229 ET Maastricht, the Netherlands
| | - Jacob G Johansen
- Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus, Denmark
| | - Ryan L Smith
- Alfred Health Radiation Oncology, Alfred Health, 55 Commercial Rd, Melbourne, VIC 3004, Australia
| | - Luc Beaulieu
- Department of Physics, Engineering Physics & Optics and Cancer Research Center, Université Laval, Quebec City, QC, Canada.,Department of Radiation Oncology, Research Center of CHU de Québec, Université Laval, Quebec City, QC, Canada
| | - Sam Beddar
- Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1420, Houston, TX 77030, United States
| | - Gustavo Kertzscher
- Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus, Denmark
| | - Frank Verhaegen
- Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, Doctor Tanslaan 12, 6229 ET Maastricht, the Netherlands
| | - Kari Tanderup
- Department of Oncology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus, Denmark
| |
Collapse
|
4
|
Izewska J, Lechner W, Wesolowska P. Global availability of dosimetry audits in radiotherapy: The IAEA dosimetry audit networks database. Phys Imaging Radiat Oncol 2018; 5:1-4. [PMID: 33458360 PMCID: PMC7807735 DOI: 10.1016/j.phro.2017.12.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Revised: 12/12/2017] [Accepted: 12/18/2017] [Indexed: 10/26/2022] Open
Abstract
The International Atomic Energy Agency (IAEA) has established a database describing activities of dosimetry audit networks (DAN) in radiotherapy. Since 2010 the data on different aspects of the dosimetry audit have been collected. This information has allowed for the analysis and comparison of current practices in dosimetry auditing activities worldwide. Overall, 79 organizations in 58 countries confirmed that they offer dosimetry audit services for radiotherapy; however, access of radiotherapy centres to the audit remains insufficient. Increased availability of audits is necessary to improve dosimetry practices, reduce the likelihood of errors and the consequences that would result for patients' health.
Collapse
Affiliation(s)
- Joanna Izewska
- International Atomic Energy Agency, Vienna International Centre, PO Box 100, A-1400 Vienna, Austria
| | | | - Paulina Wesolowska
- International Atomic Energy Agency, Vienna International Centre, PO Box 100, A-1400 Vienna, Austria
| |
Collapse
|
5
|
Affiliation(s)
- Catharine H. Clark
- Medical Physics Department, Royal Surrey County Hospital, Guildford Surrey, UK
- Metrology for Medical Physics, National Physical Laboratory, Teddington, Middx, UK
| |
Collapse
|
6
|
Muren LP. The first year achievements of Physics and Imaging in Radiation Oncology. Phys Imaging Radiat Oncol 2018; 5:111-112. [PMID: 33458379 PMCID: PMC7807658 DOI: 10.1016/j.phro.2018.03.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
- Ludvig P. Muren
- Department of Medical Physics, Aarhus University/Aarhus University Hospital, Aarhus, Denmark
| |
Collapse
|
7
|
Thomas RA, Bolt MA, Bass G, Nutbrown R, Chen T, Nisbet A, Clark CH. Radiotherapy reference dose audit in the United Kingdom by the National Physical Laboratory: 20 years of consistency and improvements. PHYSICS & IMAGING IN RADIATION ONCOLOGY 2017. [DOI: 10.1016/j.phro.2017.07.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|